Sen. Ruben Gallego (D-Ariz.) is raising concerns over the lack of details given about President Trump's "most favored nation" (MFN) pricing deal he announced with Pfizer this week, calling on the company's CEO to explain how it plans to execute the agreement.

In a letter to Pfizer CEO Albert Bourla, provided to The Hill, Gallego asked for clarity in his agreement with the Trump administration.

Bourla announced Tuesday at the White House that his company would be complying with all four of Trump's demands written out in his MFN executive order, signed in May.

The order called on manufacturers to provide preferential pricing to all Medicaid patients, required they not give better prices to other developed countries for new drugs, create direct-to-consumer sale platforms and use trade poli

See Full Page